Patient Case #2: A 77-Year-Old Man With Newly Diagnosed MM
Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.
Patient Case #1: A 75-Year-Old Woman With Newly Diagnosed MM
Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.
Treatment Options for First-Line Therapy in Transplant-Ineligible MM
In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.
Transplant-Ineligible MM: Treatment After Adequate Response to Therapy
A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.
Transplant-Ineligible Multiple Myeloma: Assessing Response to Therapy
Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.
Multiple Myeloma: Transplant Ineligibility and Goals of Therapy
Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.
Challenges in Treating Transplant-Ineligible Multiple Myeloma
Shared insight on the difficulties of transplant-ineligible newly diagnosed multiple myeloma and how to optimally approach treatment.
Peter Voorhees, MD, on Sustained MRD Negativity in the Phase 2 GRIFFIN Trial
The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).
Peter Voorhees, MD, Discusses Updated Analysis of Phase 2 GRIFFIN Trial in MM
The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.
Peter Voorhees, MD on the Progress Made in 2020 For Patients With Multiple Myeloma
Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.
Peter Voorhees, MD, Discusses Results from the Ongoing GRIFFIN Study
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma.